TY - JOUR
T1 - Dissecting the stromal signalingandregulation of myeloid cells and memory effector T cells in pancreatic cancer
AU - Blair, Alex B.
AU - Kim, Victoria M.
AU - Muth, Stephen T.
AU - Saung, May Tun
AU - Lokker, Nathalie
AU - Blouw, Barbara
AU - Armstrong, Todd D.
AU - Jaffee, Elizabeth M.
AU - Tsujikawa, Takahiro
AU - Coussens, Lisa M.
AU - He, Jin
AU - Burkhart, Richard A.
AU - Wolfgang, Christopher L.
AU - Zheng, Lei
N1 - Funding Information:
N. Lokker is an employee of and holds ownership interest (including patents) in Halozyme and AstraZeneca. B. Blouw holds ownership interest (including patents) in Halozyme Therapeutics. E.M. Jaffee reports receiving commercial research grants from Bristol-Myers Squibb, AduroBiotech, and Amgen; holds ownership interest (including patents) in AduroBiotech; and is a consultant/advisory board member for CSTONE, Genocea, and DragonFly. L. M. Coussens reports receiving commercial research grants from Acerta Pharma LLC, Deciphera Pharmaceuticals, Roche Glycart AG, and Syndax Pharmaceuticals Inc.; reports receiving other commercial research support from Plexxi-kon Inc., Pharmacyclics Inc., Acerta Pharma LLC, Deciphera Pharmaceuticals, Genentech Inc., Roche Glycart AG, Cell Signaling Technologies, and NanoString Technologies Inc.; and is a consultant/advisory board member for Pharmacyclics Inc., Syndax Pharmaceuticals Inc., Carisma Therapeutics Inc., Verseau Therapeutics Inc., Zymeworks Inc., Melvin and Bren Simon Cancer Center at Indiana University, the Koch Institute for Integrated Cancer Research at MIT, Salk Institute Cancer Center, the Bloomberg-Kimmel Institute of Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dana Farber Cancer Center Breast SPORE, Cancer Research Institute, The V Foundation for Cancer Research, Cancer Research United Kingdom, Starr Cancer Consortium, NIH/NCI, and Cell Signaling Technologies. L. Zheng reports receiving commercial research grants from Novarock, Merck, Bristol-Myers Squibb, Amgen, Halozyme, iTeos, and Inxmed; holds ownership interest (including patents) in Aduro, Minruiz-hiyao, and Alphamab; and is a consultant/advisory board member for Foundation Medicine, Novarock, Alphamab, Biosynergies, Datarevive, Sound Biologics, and Shenzhen Geno-Immune. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
We acknowledge and thank MedGenome for cost sharing of RNA sequencing efforts. This work was supported in part by a grant from Halozyme; NIH grant T32 CA126607 (to A.B. Blair and L. Zheng); NIH grant R01 CA169702 (to L. Zheng); NIH grant K23 CA148964 (to L. Zheng); NIH grant R01 CA197296 (to L. Zheng); the Viragh Foundation and the Skip Viragh Pancreatic Cancer Center at Johns Hopkins (to E.M. Jaffee and L. Zheng); the Sol Goldman Pancreatic Cancer Research Center (to L. Zheng); the Lefkofsky Family Foundation (to L. Zheng); National Cancer Institute Specialized Programs of Research Excellence in Gastrointestinal Cancers grant P50 CA062924 (to E.M. Jaffee and L. Zheng); Sidney Kimmel Comprehensive Cancer Center grant P30 CA006973 (to E.M. Jaffee and L. Zheng); and a Lustgarten Foundation grant (to L. Zheng).
Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Purpose: Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. Experimental Design: A murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20. Results:Targeting stroma by degradingHAwithPEGPH20 in combination with vaccine decreases CXCL12/CXCR4/ CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8+ T cells, respectively. This corresponds with increased CCR7+ effector memory T-cell infiltration, an increase in tumor-specific IFNg, and improved survival. In the stroma of human PDACs treated with the same vaccine, decreased stromal CXCR4 expression significantly correlated with decreased HA and increased cytotoxic activities, suggesting CXCR4 is an important therapeutic target. Conclusions: This study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity.
AB - Purpose: Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. Experimental Design: A murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20. Results:Targeting stroma by degradingHAwithPEGPH20 in combination with vaccine decreases CXCL12/CXCR4/ CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8+ T cells, respectively. This corresponds with increased CCR7+ effector memory T-cell infiltration, an increase in tumor-specific IFNg, and improved survival. In the stroma of human PDACs treated with the same vaccine, decreased stromal CXCR4 expression significantly correlated with decreased HA and increased cytotoxic activities, suggesting CXCR4 is an important therapeutic target. Conclusions: This study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity.
UR - http://www.scopus.com/inward/record.url?scp=85071783360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071783360&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-4192
DO - 10.1158/1078-0432.CCR-18-4192
M3 - Article
C2 - 31186314
AN - SCOPUS:85071783360
SN - 1078-0432
VL - 25
SP - 5351
EP - 5363
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 17
ER -